Sfmg LLC Has $3.41 Million Position in Zoetis Inc. $ZTS

Sfmg LLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,881 shares of the company’s stock after purchasing an additional 1,531 shares during the quarter. Sfmg LLC’s holdings in Zoetis were worth $3,412,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Brighton Jones LLC lifted its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares during the period. Wedbush Securities Inc. grew its stake in Zoetis by 91.0% during the first quarter. Wedbush Securities Inc. now owns 8,173 shares of the company’s stock worth $1,346,000 after buying an additional 3,895 shares during the last quarter. Pinnacle Associates Ltd. increased its holdings in shares of Zoetis by 12.9% during the first quarter. Pinnacle Associates Ltd. now owns 21,435 shares of the company’s stock worth $3,529,000 after buying an additional 2,446 shares in the last quarter. Kovack Advisors Inc. acquired a new position in shares of Zoetis in the 1st quarter worth approximately $227,000. Finally, Journey Strategic Wealth LLC grew its position in Zoetis by 16.9% during the 1st quarter. Journey Strategic Wealth LLC now owns 2,228 shares of the company’s stock worth $367,000 after acquiring an additional 322 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS opened at $122.06 on Friday. The company has a market capitalization of $53.79 billion, a price-to-earnings ratio of 21.01, a P/E/G ratio of 2.31 and a beta of 0.90. The business’s 50-day moving average price is $137.75 and its two-hundred day moving average price is $150.17. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $181.85. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter last year, the firm earned $1.58 EPS. Zoetis’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.6%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is presently 33.67%.

Analysts Set New Price Targets

Several research analysts recently weighed in on ZTS shares. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Morgan Stanley lowered their price target on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, November 10th. KeyCorp started coverage on Zoetis in a research note on Thursday. They issued a “sector weight” rating on the stock. JPMorgan Chase & Co. decreased their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, Piper Sandler upped their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Moderate Buy” and an average price target of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.